Regenerative Medicine The New Wave

By: Parker Foot Ankle

See original here:
Regenerative Medicine The New Wave - Video

Recommendation and review posted by sam

Stem Cell Hair Therapy - Hair Regrowth Treatment using Adult Stem Cell from Luminesce
Do It Yourself - Stem Cell Hair Therapy : http://placesiana.com/stem-cell-hair-loss-therapy Imagine becoming a healthier, much younger, better looking you? Infused with a potent growth factor...

By: Sam Jeunesse

Read the rest here:
Stem Cell Hair Therapy - Hair Regrowth Treatment using Adult Stem Cell from Luminesce - Video

Recommendation and review posted by simmons

Bone Marrow-Derived Stem Cell Prolotherapy
Stem Cell Prolotherapy is a procedure in which adult mesenchymal stem cells are transplanted directly into the damaged tissue or injury and promotes healing....

By: Kab S. Hong M.D.

Visit link:
Bone Marrow-Derived Stem Cell Prolotherapy - Video

Recommendation and review posted by Bethany Smith

La Jolla, CA (PRWEB) October 21, 2014

StemGenex, the leading resource for adult adipose stem cell therapy in the US aimed at improving the lives of patients dealing with degenerative diseases today announced their newest clinical study in partnership with Stem Cell Research Centre for Osteoarthritis. StemGenex and Stem Cell Research Centre (SCRC) believe that a commitment to the safety and efficacy of stem cell therapy are paramount when providing care to patients with life threatening diseases.

There are currently 21 million people in the U.S. alone, who suffer from Osteoarthritis. The most common symptoms are joint pain and stiffness which most commonly affect the neck, lower back, knees, shoulders and hips. These symptoms gradually worsen over time ultimately leading to the need for a total joint replacement procedure. StemGenex believe their new clinical study may provide patients improved mobility, significantly reduced pain and ultimately a better quality of life without needing joint replacement surgery.

This clinical study makes stem cell therapy for osteoarthritis accessible to the millions of individuals currently struggling with this painful disease. The protocol used in these stem cell treatments is unique to StemGenex and SCRC, having the possibility of being more effective than other stem cell treatments currently available. These treatments will utilize a multiple administration method which also includes injections precisely targeting the joint space. StemGenex believes these treatments may be able to keep patients from needing joint replacement surgery in the future, due to regeneration of cartilage in the joint.

This clinical study will be conducted under the leadership of the principal investigator,Dr. Jeremiah McDole, Ph.D. Dr. McDole states, We are excited to begin enrolling for this new study. We have high expectations for what we will learn and what advancements can ultimately be implemented. Of course, our focus is always set toward the near future and what can be done to help improve the lives of those individuals with Osteoarthritis.

This study is registered through The National Institutes of Health which can be found at http://www.clinicaltrials.gov and is being conducted under IRB approval of Stem Cell Research Centre (SCRC). There are many patients who are exploring stem cell therapy for osteoarthritis and it is important they have access to top-tier stem cell therapy. By providing patients access to stem cell studies registered through The National Institutes of Health, patients now have the ability to choose treatment that focuses on both safety and efficacy.

Rita Alexander, founder and president of StemGenex stated With so many people suffering from Osteoarthritis its absolutely wonderful to provide a treatment that has not only shown efficacy but also to be minimally invasive. Over the last several years we have observed significant improvement in the symptoms of Osteoarthritis patients through stem cell treatment. Through these registered clinical studies, we will now be able to publish our findings over the next few years.

This clinical study follows on the heels of StemGenex latest clinical studies for both Parkinsons disease and Multiple Sclerosis. Stem cell treatment studies are currently being offered by StemGenex partnering with Stem Cell Research Centre (SCRC) to patients diagnosed with Osteoarthritis as well as degenerative neurological diseases. StemGenex takes a unique approach of compassion and empowerment while providing access to the latest stem cell therapies for degenerative conditions including Multiple Sclerosis, Alzheimers disease, stroke recovery and others.

To find out more about stem cell therapy, contact StemGenex either by phone at (800) 609-7795 or email Contact@stemgenex.com

Here is the original post:
StemGenex New Clinical Study Aims to Provide Relief to Osteoarthritis Patients through Latest Stem Cell Therapy

Recommendation and review posted by Bethany Smith

PUBLIC RELEASE DATE:

20-Oct-2014

Contact: Todd Murphy murphyt@ohsu.edu 503-494-8231 Oregon Health & Science University @ohsunews

Oregon Health & Science University's Vaccine & Gene Therapy Institute (OHSU), has been awarded a $10 million contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Kineta, Inc., the University of Washington Center for Innate Immunity and Immune Disease (CIIID), and the Vaccine & Gene Therapy Institute of Florida (VGTI Florida) will collaborate with OHSU as major sub-contractors to develop new vaccine adjuvants that could boost the effectiveness of a wide range of human vaccines for infectious diseases including West Nile Virus, Dengue and Japanese Encephalitis. The work will also provide novel applications for enhancing the immune response against Ebola virus, HIV, and other virus infections. Infectious diseases affect millions of people in developed and developing nations, many with no effective protective vaccines.

Vaccines are the first line of defense against infectious disease and have saved millions of lives over the years. However, some people with weakened immune systems and the elderly lose the ability to respond to vaccines. The effectiveness of vaccines can be improved by the addition of substances called adjuvants that not only enhance the body's immune response to the vaccine but also decrease the dose of the vaccine, allowing the vaccine supply to be extended.

Currently, the Food and Drug Administration has approved only three vaccine adjuvants. This award is part of an NIH push to develop more adjuvants.

"Although vaccines are extremely effective at preventing disease, the elderly and infants, who are the most vulnerable part of our population, are not efficiently protected," said Jay Nelson, Ph.D., professor and director of OHSU's VGTI, who will co-lead work on the NIH contract. "For example, while 80 percent of normal healthy adults are protected with the flu vaccine, more than 40 percent of people over 65 do not develop protective immunity. We have found that the addition of adjuvants to vaccines can better protect older animals from virus infection," Nelson added.

Nelson and other OHSU VGTI scientists will work with Shawn Iadonato, Ph.D., Chief Scientific Officer for Kineta, Inc., a biotechnology company in Seattle, on the development of new adjuvants using the company's innate immune drug development platform.

"Kineta has significant experience in high through-put methods to identify chemical compounds that stimulate the immune system and that are safe and effective. Developing these new adjuvants could change the paradigm for generating lasting immunity to pathogens," said Dr. Iadonato.

Michael Gale, Jr., Ph.D., Professor of Immunology and Director of the CIIID at the University of Washington, will co-lead this project with Nelson. "The identification of new adjuvants will also be important to make vaccines for other diseases such as Ebola virus, influenza A virus, HIV, bacterial infection, and cancer more effective," Gale said.

Follow this link:
OHSU, partners Kineta, UW, VGTI Florida awarded NIH contract to develop vaccine adjuvants

Recommendation and review posted by Bethany Smith

Biotechnology 1: Genetic Engineering
First of 3 video podcasts.

By: Alan Allmen

Read more here:
Biotechnology 1: Genetic Engineering - Video

Recommendation and review posted by Bethany Smith

Proposition 105 would require mandatory GMO labeling
Under Proposition 105, food producers would be required to label foods produced with genetic engineering, or GMO #39;s. Russell Haythorn reports.

By: 7 NEWS - The Denver Channel

The rest is here:
Proposition 105 would require mandatory GMO labeling - Video

Recommendation and review posted by Bethany Smith

Last year's half-baked and unsuccessful proposal to ban genetically engineered crops in Los Angeles has not improved with time. Yet here it is before the City Council again, complete with wild statements about bioengineered food, chock full of inconsistent logic and, just like last year, rendered virtually meaningless because there are no such crops in the city and no plans to grow them.

The motion, brought to the council Tuesday by Councilmen Paul Koretz and Mitch O'Farrell, cites concern by consumers that genetically engineered food might be unsafe to eat, a position that is not backed by years of scientific study. The councilmen point out in support of their proposal that 52% of county voters favored a failed 2012 statewide proposition that would have required that labels be put on foods with bioengineered ingredients ignoring the fact that labeling a product and banning the process that created it are entirely different things.

The councilmen also complain about the herbicides used on bioengineered crops, and those complaints are partly justified. But linking that to a ban makes for foolish policy. It is true that plants have often been engineered to resist herbicides, which are then sprayed on the plants intensively and repeatedly over time. That, in turn, has given rise to herbicide-resistant weeds, which can be very difficult to eradicate in fields of conventionally grown crops. But the problem is not the genetically engineered plants, it is the heavy application of the herbicides. Conventional lawns are also heavily treated with herbicides and other chemicals that aren't good for the environment. The proper response is a regulation on pesticide and herbicide use, not a ban on the crops.

And not all genetic engineering of crops is designed to build resistance to pesticides. Scientists have, for instance, developed a form of rice that contains significant amounts of vitamin A, an innovation that could prevent blindness and death for millions of people in Asia and Africa. Scientists are at work on oranges they hope will resist citrus greening, a disease that threatens to wipe out orange groves throughout the U.S. What if future projects included drought-tolerant crops that could survive the kind of prolonged dry spell California has been experiencing? Why would we want to ban such products without any scientific indication that they're unhealthy or unsafe?

That's not to say all bioengineered plants are keepers. Herbicide-resistant turf grass is undergoing product testing. But because grasses spread easily, there should be concern that the engineered products could take over neighbors' lawns and become omnipresent pests even in the wilderness areas that surround the city.

In other words, making sound policy requires lawmakers to rise above irrational fears and easy generalizations and to become informed about science.

Follow the Opinion section on Twitter @latimesopinion

See the original post:
Sowing the seeds of an illogical crop ban

Recommendation and review posted by Bethany Smith

Harvard Medical School professor George M. Church discussed the possibilities and potential dangers of genetic engineering on Wednesday. The lecture event, presented by the Harvard Museum of Natural History, covered a range of topics, including potential gains for genetic information and technologies and considerations of ethics and efficacy.

Church began the evening by highlighting the importance of genome testing, stressing that whether or not you have family history, whether or not you [are of] a particular ethnicity, all of us are at risk for rare diseases.

Genome testing has made advances in recent years, with the cost of sequencing an individuals genome having decreased in the past decade.But further advances in genome testing, Church said, could allow us to essentially see whats currently invisible, to essentially see the genomes around us.

Advances in the portability and affordability of genome testing, for instance, could lead to a sort of handheld DNA sequencing device that could dramatically impact diagnostics and field studies.

Moreover, Church said, if you have an inexpensive way of [sequencing genomes] you can really start testing a lot of ideas about cause and effect, with the potential to identify rare protective gene variants that could alleviate or eliminate some diseases.

Your genetics is not your destiny, Church said.

Church also discussed the possibility of de-extinction, bringing back species like the woolly mammoth. He predicted that the de-extinction process would largely depend on both ecological and economic considerations, in which species are judged both on their viability in modern ecosystems and their utility. He highlighted the woolly mammoth as an example of such a keystone species that could dramatically and positively impact the global ecosystem, citing his 2013 Scientific American article which outlined how mammoths could contribute to the reversal of global warming by keeping the tundra frozen.

Letting the tundra melt, Church said, is the equivalent to burning all of the forests in all of the world and their roots two and a half times over. Bringing back the woolly mammoth could be one important step toward preventing this catastrophic release of carbon, according to Church.

Church also briefly touched on human genetic enhancements, noting that changes in the modern environment and human behavior have framed the topic of altering ones genome in terms of necessity.

Our ancestors didnt need any genetic enhancements to be able to sit for twelve hours a day and eat fatty, sugary foods, but we need enhancements that handle that altered environment, he said. If we go into space, we need enhancements that handle radiation and osteoporosis...or else were dead. So what seems like an enhancement in one generation becomes life and death in another generation.

Go here to read the rest:
Professor Outlines Risks, Benefits of Genome Editing

Recommendation and review posted by Bethany Smith

RAR Genetics - New Direction

By: EDJE Technologies

Go here to read the rest:
RAR Genetics - New Direction - Video

Recommendation and review posted by Bethany Smith

Neuroscience Symposium: Genetics in psychiatry
Participants at the Neuroscience Symposium shed light on how genetics are influencing our understanding of psychiatry and what this means for diseases such as schizophrenia. The Roche Pharma...

By: Roche

Continued here:
Neuroscience Symposium: Genetics in psychiatry - Video

Recommendation and review posted by Bethany Smith

A new variation of gene therapy raises hopes for a safe and effective long-term treatment for X-linked severe combined immunodeficiency syndrome (SCID-X1), a life-threatening heritable disorder.

The research was produced by a collaborative research team from Dana-Farber/Boston Children's Cancer and Blood Disorders Center, along with other institutions participating in an international clinical trial that involved boys from the United States and France.

SCID-X1, dubbed bubble boy disease after a patient who lived for 12 years in a sterile bubble, is a rare genetic disorder that hinders the ability of individuals to combat infections. Because the disease is carried in an X-chromosome recessive pattern, the disorder occurs almost only in males. The resulting mutations inactivate a gene called IL-2 receptor gamma (IL2RG), severely weakening immune system functions. Left untreated, individuals who inherit the disorder usually die within a year.

Previous gene therapy trials conducted in Europe over a decade ago promised dramatic progress, until a quarter of patients developed leukemia about two to five years following treatment. Scientists found that the previously used vectorthe device for transporting the correct gene in therapyinadvertently activated oncogenes, which can cause cancer.

In this new study, the vector in use is a self-inactivating gammaretrovirus, which has a specific sequence deleted that basic research had implicated in the process of inappropriate activation of oncogenes, David A. Williams, chief of the hematology/oncology department at Boston Children's Hospital, wrote in an email.

Of the nine patients who underwent the treatment, eight had survived between 12 and 38 months after treatment. One boy died from a severe infection he was fighting at the time he enrolled in the study.

A single round of therapy restored normal disease-fighting T cell count300 cells or more per microliter of bloodin six of the eight patients. One patient underwent a second round of treatment and remains healthy despite a low cell count. The eighth patient received a hematopoietic stem cell transplant after the therapy led to less than optimal uptake of the virus and failed to stimulate T-cell production, according to Williams.

We feel the surrogate assays for safety look excellent and are very encouraged, Williams said. However, because leukemia can take years to develop (and although some of our patients are now approaching 4 years of [follow-up]) we must be cautious and continue to follow these children closely.

Williams noted that the research was the result of positive collaboration between institutions.

Work by Sung-Yun Pai and Gigi Notarangelo, funding from [Boston Childrens Hospital] (and other childrens hospitals) and [the National Institute of Health] were essential for success, he said. This is the first international collaborative trial in stem cell gene therapy, which was critical for success due [to the] rarity of [this] disease.

Original post:
With Collaboration, Scientists Test Gene Therapy for 'Bubble Boy Disease'

Recommendation and review posted by Bethany Smith

treatment for spinal cord injury
6 months after treatment for spinal cord injury by dr alok sharma gains sensations. Treatment done at Dr Alok Sharma NeuroGen Brain and Spine Institute StemA...

By: Neurogen Brain and Spine Institute

Continued here:
treatment for spinal cord injury - Video

Recommendation and review posted by sam

An accident, a broken neck, then medical school
As part of Yale Medicine #39;s ongoing discussion of resilience, Yale medical student Chris Zirker, who survived a spinal cord injury while in college, talks about how his injury affected his life...

By: YaleMedicine

See the article here:
An accident, a broken neck, then medical school - Video

Recommendation and review posted by sam

Spinal Cord Injury Treatments - Neurofit 360 Rehabilitation - Gym for the Disabled
NeuroFit 360 is a wellness gym in south Florida dedicated to helping those who have suffered a neurological or spinal cord injury. Graham Faught suffered a s...

By: Guy Romain

Go here to read the rest:
Spinal Cord Injury Treatments - Neurofit 360 Rehabilitation - Gym for the Disabled - Video

Recommendation and review posted by sam

USC #39;s Jon-Paul Pepper is a surgeon, scientist, student and award-winner
USC #39;s Jon-Paul Pepper is not the average award winner. He #39;s also not the average facial plastic surgeon, faculty researcher or master #39;s student in part, because he #39;s currently all...

By: USC

Go here to read the rest:
USC's Jon-Paul Pepper is a surgeon, scientist, student and award-winner - Video

Recommendation and review posted by sam

Stem Cell Treatment | Multiple Sclerosis | http://www.stemrx.in
Multiple sclerosis (MS), also known as disseminated sclerosis or encephalomyelitis disseminata, is an inflammatory disease in which the insulating covers of ...

By: StemRx BioScience

See the article here:
Stem Cell Treatment | Multiple Sclerosis | http://www.stemrx.in - Video

Recommendation and review posted by simmons

PUBLIC RELEASE DATE:

20-Oct-2014

Contact: David McKeon 212-365-7440 New York Stem Cell Foundation @nyscf

Leaders in translational stem cell research from around the world will present the latest advances in stem cell science that are leading to better treatments and cures to disease and injury at The New York Stem Cell Foundation's Ninth Annual Translational Stem Cell Research Conference.

The opening day of the conference includes a panel discussion on large scale, big data stem cell and genetic initiatives moderated by Susan L. Solomon, JD, CEO and Co-founder of The New York Stem Cell Foundation (NYSCF), with panelists George Church, PhD, Harvard Medical School; John Greally, PhD, Albert Einstein College of Medicine; Scott Noggle, PhD, The NYSCF Research Institute; and Eric Schadt, PhD, the Icahn School of Medicine at Mount Sinai.

Later that day, a discussion on neurodegeneration includes Kevin Eggan, PhD, Harvard University and the NYSCF Research Institute, who will discuss his research identifying an existing drug candidate that may be of use treating ALS and is entering clinical trials in the coming year. The following session on cell reprogramming and cancer includes Michael Milone, MD, PhD, University of Pennsylvania, who will discuss recent research results from his lab and his colleagues including the results of a clinical trial for leukemia featured in The New York Times last week. The first day closes with a conversation on personalized medicine featuring Dieter Egli, PhD, NYSCF Robertson Investigator at the NYSCF Research Institute and Columbia University; Rudolf Jaenisch, MD, The Whitehead Institute; and Sir Ian Wilmut, FRS, FRSE, University of Edinburgh.

On October 23, the day will begin with remarks by Kenneth Adams and Kyle Kimball, President of the Empire State Development Corporation and President of the New York City Economic Development Corporation, respectively. The session on translating innovation from the laboratory to the clinic features Stephen Chang, PhD, of the NYSCF Research Institute and Richard Pearse, PhD, of the Harvard Catalyst and eagle-i Network who will discuss their collaboration on the first publicly available induced pluripotent stem cell database. The day will close with a presentation on induced neuronal cells and cell transdifferentiation from the 2014 NYSCF Robertson Stem Cell Prize recipient, Marius Wernig, MD, PhD, of Stanford University School of Medicine.

Sir Ian Wilmut will give the keynote address on October 22nd and Dr. Rudolf Jaenisch will give the keynote address on the last day of the conference.

The full conference agenda can be found at http://www.nyscf.org/conference

###

See the rest here:
Stem cell and clinical research advances to be presented at NYSCF's Ninth Annual Conference

Recommendation and review posted by simmons

Why patients should be excited about precision oncology
What does precision oncology or personalized medicine for cancer really mean for now and the future? A leading breast cancer expert from Italy shares his global view from the ESMO congress...

By: Patient Power

See original here:
Why patients should be excited about precision oncology - Video

Recommendation and review posted by sam

Meet Michael Snyder
Michael Snyder is the Stanford Ascherman Professor and Chair of Genetics and the Director of the Center of Genomics and Personalized Medicine. Dr. Snyder received his Ph.D. training at the...

By: stanfordonline

Read the original post:
Meet Michael Snyder - Video

Recommendation and review posted by sam

ChemoFx: Personalizing Your Cancer Treatment
Personalized medicine tools are changing the way gynecologic cancers are diagnosed and treated. ChemoFx is a lab test that measures the response of cancer cells to cancer drugs. While not ...

By: Precision Therapeutics

More here:
ChemoFx: Personalizing Your Cancer Treatment - Video

Recommendation and review posted by sam

Stick Tap To Hope
Join us November 1st at Xcel Energy Center for A NIGHT TO BEL13VE as we Stick Tap To Hope and move Spinal Cord Injury recovery forward. Learn more at http://www.bel13vefoundation.org.

By: BEL13VERS

More:
Stick Tap To Hope - Video

Recommendation and review posted by sam

Project Walk Client Highlight - Leonie S. C5 Spinal Cord Injury
Leonie was able to do full squats with limited assistance! For more information on starting a Project Walk program please visit http://www.ProjectWalk.com and fill ...

By: Project Walk

Read this article:
Project Walk Client Highlight - Leonie S. C5 Spinal Cord Injury - Video

Recommendation and review posted by sam

"Chris Inspires Us" (Feat. Luther College Athletes)
Today, October 16th, marks the fourth year since Chris Norton experienced his spinal cord injury. He was initially given a 3% chance of moving anything below the neck. For more information...

By: Chris Norton

Read more:
"Chris Inspires Us" (Feat. Luther College Athletes) - Video

Recommendation and review posted by sam

2014 GOAL Award Neuroplasticity Collaboration
Connecting Minds. Exchanging Ideas. A Madonna Rehabilitation Hospital University of Nebraska-Lincoln collaboration in neuroscience research rehabilitation. Neuroplasticity is the brain #39;s...

By: MadonnaRehab

Continued here:
2014 GOAL Award Neuroplasticity Collaboration - Video

Recommendation and review posted by sam